Imaging with Fluciclovine PET/CT May Improve Radiation Targeting in Recurrent Prostate Cancer

Imaging with Fluciclovine PET/CT May Improve Radiation Targeting in Recurrent Prostate Cancer
Patients receiving radiation therapy for recurrent prostate cancer after prostatectomy may have better outcomes if imaging with the positron emission tomography (PET) radiotracer fluciclovine is used to guide their treatment. Results from an ongoing study show that assessing tumors with fluciclovine PET/CT scans leads to significant differences in the areas to receive radiotherapy, compared to conventional computed tomography (CT) or magnetic resonance imaging (MRI) techniques, with similar toxicities. The study, "Impact of 18F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial," was published in The Journal of Nuclear Medicine. "This is the first study of its kind demonstrating changes in post-surgery radiotherapy target design with advanced molecular imaging in recurrent prostate cancer, with no demonstrated increase in early radiotherapy side effects," Ashesh B. Jani, MD, of the Winship Cancer Institute of Emory University in Atlanta, Georgia, said in a news release. Radical prostatectomy and radiotherapy are the two main curative options for localized prostate cancer. Radiation therapy, in particular, can either be administered right after the surgery, or when a patient's cancer returns following surgery. While CT and MRI are commonly used to detect the areas of high risk that should receive radiation therapy, they have low sensitivity, and better imagi
Subscribe or to access all post and page content.